Get the Stockscreener App
5.16
3.19%
-0.17
Personalis Inc stock is traded at $5.16, with a volume of 505.11K.
It is down -3.19% in the last 24 hours and down -19.50% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$5.33
Open:
$5.5
24h Volume:
505.11K
Relative Volume:
0.45
Market Cap:
$437.02M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.2933
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
-3.73%
1M Performance:
-19.50%
6M Performance:
+61.25%
1Y Performance:
+316.13%
1-Day Range:
$5.16
$5.62
1-Week Range:
$4.815
$5.62
52-Week Range:
$1.12
$7.20
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
5.16 | 437.02M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
572.71 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.01 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.64 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
209.96 | 38.11B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
460.56 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Wall Street analysts’ outlook for Personalis Inc (PSNL) - SETE News
Should You Expect A Quick Recovery From Personalis Inc (NASDAQ: PSNL) After -35.08% Decline From High? - Marketing Sentinel
Personalis Inc (PSNL) is a good investment, but the stock may be overvalued - US Post News
Needham analysts upgrades a Buy rating for Personalis Inc (PSNL) - Knox Daily
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
FY2024 EPS Estimates for Personalis Lowered by HC Wainwright - MarketBeat
Analysts Issue Forecasts for Personalis FY2029 Earnings - MarketBeat
FY2024 EPS Estimates for Personalis Reduced by HC Wainwright - Defense World
Personalis price target lowered to $8 from $11 at H.C. Wainwright - MSN
Brokers Set Expectations for Personalis FY2029 Earnings - Defense World
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Marketscreener.com
Precision Oncology Leader Personalis Takes Center Stage at Major Healthcare Summit - StockTitan
Personalis stock price target cut to $8 by H.C. Wainwright - MSN
Personalis (NASDAQ:PSNL) Given New $8.00 Price Target at HC Wainwright - Defense World
Personalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
HC Wainwright Cuts Personalis (NASDAQ:PSNL) Price Target to $8.00 - MarketBeat
Personalis (PSNL) Upgraded to Buy: Here's Why - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Stock Position Increased by Barclays PLC - Defense World
Researchers find ctDNA test predicts lung cancer outcomes in study - Yahoo Finance
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer - sharewise
Catherine Wood's Strategic Acquisition of Personalis Inc Shares - GuruFocus.com
Personalis Lung Cancer Test Shows 100% Detection Rate in Breakthrough Study - StockTitan
Personalis (NASDAQ:PSNL) Stock Price Expected to Rise, Lake Street Capital Analyst Says - Defense World
Personalis stock target lifted, retains buy on impressive performance By Investing.com - Investing.com Canada
Personalis (NASDAQ:PSNL) Price Target Raised to $9.00 - MarketBeat
Personalis stock target lifted, retains buy on impressive performance - Investing.com India
Personalis (NASDAQ:PSNL) Earns Buy Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Geode Capital Management LLC Buys 83,068 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue - The Bakersfield Californian
Personalis Beats 2024 Revenue Guidance with 15% Growth, Secures Moderna Partnership - StockTitan
Barclays PLC Buys 20,444 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by State Street Corp - Defense World
Jane Street Group LLC Increases Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stock Position Reduced by Stifel Financial Corp - Defense World
Personalis, Inc. Amends Sales Agreement with Piper Sandler & Co. and BTIG - Defense World
The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159% - Yahoo Finance
Grail (NASDAQ:GRAL) & Personalis (NASDAQ:PSNL) Financial Contrast - Defense World
Local vaccine biotech secures $50 million Merck investment - The Business Journals
Personalis price target raised to $8 from $7 at BTIG - Yahoo Finance
Personalis Announces Investment Agreement with Merck in Latest 8-K Filing - Defense World
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):